AVBP Stock — ArriVent BioPharma Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers.

Source: 10-K FY2025 via SEC EDGAR

Share price

$13.64

Market cap

$672.6M

Cash

$373.1M

Enterprise value

$299.5M

Balance sheet

Cash	$373.1M
Debt	$0.0M
Net cash	$373.1M
Enterprise value	$299.5M
Basic shares	49.3M shares
Fully diluted shares	58.1M shares
Fully diluted market cap	$792.6M
Cash per share	$7.57
Quarterly burn	$39.6M
Cash runway	9.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

49.3M

Pre-funded warrants

1.5M

Options

7.3M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

58.1M

Cap table as of 2026-08-10.

Price history

Loading AVBP daily closes…

Loading price history…

Next catalyst

ARR-002 · Sep 12 - Oct 24 in 10 mo · Phase 1 · Ovarian Cancer; Endometrial Cancer; Platinum-resistant Ovarian Cancer (PROC)

Recently reported

Firmonertinib Phase 1b Positive · 2026-10-19

FURTHER (FURMO-002) · treatment-naive advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC)

Primary: Confirmed overall response rate (ORR) and progression-free survival (PFS) by blinded independent central review (BICR); the release does not designate a single primary endpoint — Confirmed ORR 43% at 160 mg and 68% at 240 mg; median PFS 11.1 months at 160 mg and 16.0 months at 240 mg (both by BICR)

· Confirmed intracranial ORR 47% (8/17), including 41% complete responses among 17 patients with baseline brain metastases

· 80% of evaluable patients achieved complete molecular (ctDNA) response by cycle 3

· ctDNA clearance by cycle 3 was associated with ORR 70% vs. 20% and median PFS 15.1 vs. 3.0 months versus no clearance

· EGFR PACC mutations account for approximately 12% of EGFR-mutant tumors; no established targeted standard of care in first line

· Global Phase 3 ALPACCA trial (FURMO-006, NCT07185997) enrolling: firmonertinib vs. investigator's choice of osimertinib or afatinib

Safety: Manageable safety profile consistent with prior firmonertinib studies; no specific adverse-event rates disclosed in the release

Source release →

Firmonertinib Phase 1 Mixed · 2026-10-19

FURMO-002 · FURMO-002

Primary: Confirmed overall response rate (ORR) by blinded independent central review (BICR) in treatment-naive advanced EGFR PACC-mutant NSCLC (FURTHER Phase 1b, FURMO-002, firmonertinib) — 43% (160 mg) and 68% (240 mg) confirmed overall response rate (ORR), with 11.1- and 16.0-months median progression free survival (PFS), both by blinded independent central review (BICR)

· 47% (8/17) confirmed intracranial ORR, including 41% complete responses among 17 patients with baseline brain metastases

· 80% of evaluable patients achieved complete molecular response by cycle 3

· Patients with ctDNA clearance had higher ORR (70% vs. 20%) and longer median PFS (15.1 vs. 3.0 months) than those without clearance

· Global Phase 3 ALPACCA trial (FURMO-006, NCT07185997) enrolling firmonertinib versus investigator's choice of osimertinib or afatinib

Safety: Manageable, consistent safety profile; treatment-related adverse event rates were consistent with firmonertinib's safety profile in prior clinical studies

Source release →

firmonertinib 240 mg oral, daily Phase 3 Negative · 2026-10-06

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 12 - Oct 24 in 10 mo	ARR-002	Phase 1	Ovarian Cancer; Endometrial Cancer; Platinum-resistant Ovarian Cancer (PROC)	—
Apr 12 - May 24 in 17 mo	MRG007	Phase 1	Locally Advanced or Metastatic Solid Tumors; Colorectal Cancer; Gastric Cancer	—
Dec 12, 2028 - Jan 23, 2029 in 26 mo	Firmonertinib	Phase 3	NSCLC; Adjuvant Treatment	—
Mar 15 - Apr 26 in 29 mo	Firmonertinib	Phase 3	Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

firmonertinib

Phase 3 · Active Modality: tyrosine kinase inhibitor (third-generation)

Target EGFR

Partnerships Shanghai Allist Pharmaceuticals: exclusive license ex-Greater China ($40M upfront + 1,276,250 shares; $10M clinical milestones achieved to date; Joint Clinical Collaboration cost-sharing)

Indications

Non-small cell lung cancer (NSCLC) with EGFR mutations (Phase 3)

Status note Lead development candidate; R&D spend includes a Phase 3 Trials line item. No dated readout guidance stated in this filing.

ARR-002

Discovery · Active Modality: antibody-drug conjugate (ADC)

Target MUC16/NaPi2b

Partnerships Aarvik Pharmaceuticals: exclusive option exercised Aug 2024 ($1M option payment; up to $18M/product clinical+regulatory milestones, $80M/product commercial, mid-single-digit royalties)

Indications

Ovarian Cancer (Phase 1)
Endometrial Cancer (Phase 1)
Platinum-resistant Ovarian Cancer (PROC) (Phase 1)

Status note Novel tetravalent MUC16/NaPi2b-targeting ADC discovered through the Aarvik collaboration.

ARR-217

Stage not disclosed · Active Modality: antibody-drug conjugate (ADC)

Target CDH17

Partnerships Lepu Biopharma: exclusive license for GI cancers outside Greater China ($12M developmental milestones earned in 1H 2026; $1M first developmental milestone paid in Q2 2025)

Indications

Gastrointestinal cancers (Stage not disclosed)

Status note In development under the Lepu agreement; the filing states no clinical stage.

Alphamab ADC program (targets undisclosed)

Discovery · Active Modality: antibody-drug conjugate (ADC)

Partnerships Jiangsu Alphamab Biopharmaceuticals: ADC discovery collaboration (two target pairs approved; $1.2M paid per target pair selection in 1H 2025)

Indications

Cancers (Discovery)

Status note Early discovery-stage collaboration; no named candidate yet.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	furmonertinib 240 mg oral, daily
Lead indication	Metastatic Non-Small Cell Lung Cancer
Lead phase	Phase 3
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07185997	Phase 3	Recruiting	Sponsor	AVBP	—	Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer	—
NCT05607550	Phase 3	Active, not recruiting	Sponsor	AVBP	—	Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations	2H 2026
NCT07755436	Phase 1	Recruiting	Sponsor	AVBP	—	Ovarian Cancer; Endometrial Cancer; Platinum-resistant Ovarian Cancer (PROC)	—
NCT07066657	Phase 1	Recruiting	Sponsor	AVBP	—	Locally Advanced or Metastatic Solid Tumors; Colorectal Cancer; Gastric Cancer	—
NCT05364073	Phase 1	Active, not recruiting	Sponsor	AVBP	—	Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer	—
NCT07010419	Phase 3	Recruiting	Collaborator	Allist Pharmaceuticals, Inc.	—	NSCLC; Adjuvant Treatment	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for ArriVent BioPharma, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	3,027,328	no change	1.99%	2026-08-14
Vivo Capital	1,682,097	+796,181	5.34%	2026-08-14
Logos Global Management	1,000,000	+650,000	1.50%	2026-08-14
ADAR1 Capital Management	0	-141,814	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

AVBP — ArriVent BioPharma Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

AVBP — ArriVent BioPharma Inc.